Nonobstructive azoospermia (NOA) is a severe form of male infertility, characterized by the absence of sperm in the ejaculate due to impaired spermatogenesis. This condition stems from either intrinsic testicular failure or insufficient gonadotropin production. However, advances in reproductive medicine, specifically microsurgical testicular sperm extraction (microTESE), offer hope for men with NOA by providing a potential path to biological fatherhood.
According to the latest guidelines from the American Urological Association and the American Society for Reproductive Medicine, men diagnosed with NOA should be considered candidates for microTESE. This procedure involves surgically retrieving sperm directly from the seminiferous tubules within the testes, offering a targeted approach to overcoming this form of infertility.
Despite the absence of detectable sperm in the semen of NOA patients, there may be small, localized areas within the testes where sperm is produced. During the microTESE procedure, a surgeon meticulously searches for sperm using an operating microscope, which magnifies the surgical field 10 to 15 times. A technologist specializing in reproductive endocrinology may spend up to 14 hours examining samples under a bench-top microscope to identify viable sperm.
MicroTESE has an overall sperm retrieval success rate of 40% to 60%. Any sperm found during the procedure is used for in vitro fertilization (IVF) in conjunction with intracytoplasmic sperm injection (ICSI), a specialized technique to aid fertilization. Because of the technical complexity of microTESE, the procedure is typically performed in conjunction with reproductive endocrinologists at specialized medical facilities. Traditionally, microTESE has been conducted in an operating room under general anesthesia, which can create a financial burden for couples, especially those without insurance coverage for fertility treatments.
At the Mayo Clinic in Rochester, Minnesota, Dr. Sevann Helo has pioneered a more accessible and cost-effective approach to microTESE by performing the procedure in an office setting, using oral sedation and a 3D surgical microscope. Dr. Helo highlights the financial benefits, noting, “It’s a game-changer for patients who are paying out of pocket for a procedure that can cost upwards of $10,000 when done in the operating room, with no guarantee of finding sperm. By moving the procedure to an office setting, we’ve been able to significantly reduce the cost, making microTESE and IVF-ICSI more attainable for many couples.”
When discussing the challenges of transitioning this procedure out of the operating room, Dr. Helo emphasized the continuity in patient care: “The move to the office was a natural progression, as I already offer other microsurgical procedures, like vasectomy reversals and varicocelectomies, in the same setting. While there are some complexities in managing patient comfort during microTESE, the feedback from patients has been overwhelmingly positive. They appreciate receiving world-class care at a more affordable price.”
This innovative shift not only reduces costs but also broadens access to microTESE for couples seeking fertility treatments, offering renewed hope for those affected by nonobstructive azoospermia.
Related topics:
